Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Catalent and Verastem Partner on Newly Launched Cancer Treatment

By Mike Botta | October 17, 2018

Catalent Pharma Solutions has partnered with Verastem Oncology for development and delivery of Copiktra (duvelisib) capsules, Verastem’s first new product approved recently by the U.S. Food and Drug Administration.

Copiktra is an oral inhibitor of phosphoinositide 3-kinase (PI3K) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies. The drug also received accelerated approval for the treatment of adults with relapsed or refractory follicular lymphoma after at least two prior systemic therapies, with continued approval subject to verification and clinical benefit in confirmatory trials.

Catalent has had a multi-year collaboration with Verastem Oncology, initially providing development and analytical support, and later clinical development and manufacturing services from its Kansas City facility, which is focused on oral and biologic programs, primarily with smaller pharmaceutical firms.

The 450,000 square-foot Catalent facility provides a range of support services, from formulation development and analytical testing, to clinical- and commercial-scale manufacturing and packaging of various oral dose forms.

“We selected Catalent as our development partner because of their experience and record of bringing similar therapies through clinical trials and on to successful commercialization,” Robert Forrester, president and CEO of Verastem, said.

CLL/SLL mostly affects elderly patients and many are unable or unwilling to be hospitalized or come into the clinic for frequent IV infusions, Diep Le, M.D., Ph.D., Verastem chief medical officer, said in December discussing Phase III duvelisib trial results. He added that the CLL/SLL treatment landscape is moving away from chemotherapies and toward more targeted, preferably oral regimens.

Copiktra will be available in the U.S. market immediately, according to the company.

(Sources: Catalent Pharma Solutions; Verastem Oncology)

Related Articles Read More >

Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Cambridge Pharma launches with UK plant in Cambridge Research Park
Entegris logo
Entegris opens Life Sciences Technology Center in Massachusetts
sustainability
How pharma can optimize for right-the-first-time drug manufacturing and sustainability

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards